Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Sionna Therapeutics, Inc.NASDAQ: SION
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $1.89M fell 99.1% year over year, behind the -97.4% change in trailing-twelve-month financing cash flow. Sequentially, it rose 14.1% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -99.1% toward the trailing-twelve-month pace of -97.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 205.71M USD
- Year-over-year change
- +14.9%
- 3-year CAGR
- +22.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 205.71M | +14.9% |
| FY2024 | 2024-12-31 | 178.97M | +577212.9% |
| FY2023 | 2023-12-31 | 31K | -100.0% |
| FY2022 | 2022-12-31 | 110.86M | — |
Financing Cash Flow vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 financing cash flow of $5.21M is the smallest of the 11 companies compared; the peer median is $259.23M.
- Its year-over-year change of -97.4% is the 10th highest of 11, against a peer median of +48.8%.
- Over three fiscal years its annual growth of +22.9% compares with a peer median of +17.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $444.83M | +5357.5% | — | 167.2% | |
| LTM Sep 2026 | $436.09M | +91.6% | +2614.9% | — | |
| LTM Jun 2026 | $371.73M | -38.4% | -17.0% | — | |
| LTM Sep 2026 | $327.45M | +22878.8% | -16.3% | 292364.3% | |
| LTM Jun 2026 | $292.94M | -15.9% | +44.7% | — | |
| LTM Sep 2026 | $225.53M | +1498.5% | — | 332.4% | |
| LTM Mar 2026 | $190.32M | -2.7% | +442.1% | 951.6% | |
| LTM Mar 2026 | $58.47M | +6.1% | -10.2% | 13.7% | |
| LTM Mar 2026 | $7.94M | -98.0% | +114.7% | 36.7% | |
| LTM Mar 2026 | $5.69M | +363.0% | -55.3% | 1.8% | |
| LTM Mar 2026 | $5.21M | -97.4% | +22.9% | — | |
| Peer median (excluding SION) | $259.23M | +48.8% | +17.2% | 167.2% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.